Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • suefo
    Member
    • Jul 2011
    • 36

    #1

    emPCR thermal cycler settings

    We are experiencing high enrichment with our emPCR as well as a high %Short when we achieve an enrichment that allows us to sequence (GS Junior). We have examined our PCR plates, we have used different thermal cyclers and we have tried different tissuelysers / turraxes (looking at emulsion formation) and nothing seems to provide any clues. The only parameter we haven't really played with are the temperatures, times and number of cycles the thermal cyclers of the program.

    We are using the temps, times and cycles as outlined in the Roche protocol for em PCR (LVs, MVs, SVs and Junior kits). We are looking at 16S Amplicons. Has anyone else looked at this and use different temps, times and cycles?
  • RCJK
    Senior Member
    • May 2009
    • 156

    #2
    Hi suefo, you should only need to adjust the emPCR parameters if you are working with short or long amplicons. Have a look at their amplicon guidelines as well as technical bulletin 2011-001 (geared towards Lib-A amplicons though). I had a project in which the amplicons were ~180bp-300bp and results improved a lot when we used the short emPCR recipes and cycling parameters compared to the "normal" conditions and recipes.

    Comment

    • suefo
      Member
      • Jul 2011
      • 36

      #3
      RCJK... thanks. I will check out the technical bulletin. We are looking at amplicons in the 550-600 bp range and we are using the Lib-L kits.

      Comment

      • RCJK
        Senior Member
        • May 2009
        • 156

        #4
        Also, how high of a %short are you seeing? I do tend to see many more reads filtered out for amplicon samples than shotgun samples. Are the amplicons made with fusion primers or ligated adaptors? It may be worth doing a 2nd round of small fragment removal with the Ampure XP beads. If enrichment recoveries are high, reduce the cpb input.
        I've sequenced Lib-L amplicons of ~550bp fine using the normal emPCR conditions, though that is approaching their suggested cut off for using the long emPCR conditions. I have been told though that they have not been tested for Lib-L amplicons. Maybe you could follow the Lib-L emPCR conditions of the FLX+ protocols which should be for longer fragments (but maybe yours are not long enough).
        Lastly, if the run yields are low, depending on your application you can modify the filtering parameters to trim the amplicon reads instead of rejecting them. This should also be addressed in the updated amplicon guidelines.
        Hope this helps!

        Comment

        • suefo
          Member
          • Jul 2011
          • 36

          #5
          Thanks again RCJK.
          Our %Short is around 60% (%Dot+Mix is at 15%).
          We do perform an initial AMPure, run the products on the Agilent, pool DNA, re-purify a second time using AMPure and then run a final high-sensitivity Agilent test. Our samples appear to be extremely clean.
          We have lowered our cpb down 0.05 and our %enrichment is between 13-18%. This is of course using the Junior and the Junior kits.
          We also perform a second run of analysis loosening the filtering parameters which really only impacts the %short reducing it 4-8% from the original Amplicon analysis.
          I believe we are using ligated adaptors - but I will double check on that.

          Roche has wanted us to try their FLX+ kits. Perhaps I should suggest they send us a few test samples to see if that helps.

          I'm new to this technology. My understanding is that once the sequencing is completed they run it through another analysis package that trims the bases down even further and that there may not be too much concern about the %short. We are currently looking at sequencing data obtained off our Junior with previous data generated off the FLX to see if this is the case.

          Comment

          • suefo
            Member
            • Jul 2011
            • 36

            #6
            Ooops... I stand corrected on our length. I just re-checked the agilent data and it appears the DNA being submitted for testing is 650 bp (that's including the PCR adaptors, barcodes and keys).

            Comment

            • flxlex
              Moderator
              • Nov 2008
              • 412

              #7
              Originally posted by suefo View Post
              Roche has wanted us to try their FLX+ kits. Perhaps I should suggest they send us a few test samples to see if that helps.
              Are you sure? AFAIK, FLX+ is not available for either GS Junior, or amplicon runs?

              Comment

              • g861@hotmail.com
                Junior Member
                • Jun 2011
                • 6

                #8
                60% reads is very higher. The Roche protocol shows more than 20% is failed.
                Do you try to change primer volume? or dilute lower concentration of DNA library?
                Mandy:rolleyes:

                Comment

                Latest Articles

                Collapse

                • SEQadmin2
                  Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
                  by SEQadmin2



                  CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

                  Despite this, “CRISPR helped turn genome editing from a specialized technique into
                  ...
                  07-31-2026, 11:01 AM
                • SEQadmin2
                  Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                  by SEQadmin2


                  Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                  The systematic characterization of the human proteome has
                  ...
                  07-20-2026, 11:48 AM

                ad_right_rmr

                Collapse

                News

                Collapse

                Topics Statistics Last Post
                Started by SEQadmin2, Yesterday, 10:35 AM
                0 responses
                7 views
                0 reactions
                Last Post SEQadmin2  
                Started by SEQadmin2, 08-06-2026, 07:41 AM
                0 responses
                24 views
                0 reactions
                Last Post SEQadmin2  
                Started by SEQadmin2, 08-03-2026, 10:13 AM
                0 responses
                43 views
                0 reactions
                Last Post SEQadmin2  
                Started by SEQadmin2, 07-31-2026, 02:55 AM
                0 responses
                48 views
                0 reactions
                Last Post SEQadmin2  
                Working...